American Statistical Association
A recent phase III clinical trial in AML demonstrated an overall survival benefit for patients receiving dose-intensified daunorubicin compared to standard dosing. However, the original report of the clinical trial noted that patients with unfavorable cytogenetics appeared to receive little survival benefit from the high dose arm. With a number of novel molecular biomarkers recently identified, it may be of clinical interest to explore whether there are other subgroups who receive little benefit from the more toxic dose-intensified therapy. We will review different tree-based methods to explore interactions between biomarkers and an intervention for censored survival data. The tree-based approaches will be illustrated using the phase III AML dataset.
|Date:||Wednesday, February 6, 2013|
|Time:||11:00 A.M. - 12:00 P.M.|
Memorial Sloan-Kettering Cancer Center
Department of Epidemiology and Biostatistics
307 East 63rd Street
(between First and Second Avenues)
3rd Floor Conference Room
New York, New York
Note: To gain access to the building, please follow the directions by the telephone in the foyer.